|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Diener MK, Combs SE and Büchler MW:
Chemoradiotherapy for locally advanced pancreatic cancer. Lancet
Oncol. 14:269–270. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Akimoto M, Iizuka M, Kanematsu R, Yoshida
M and Takenaga K: Anticancer effect of ginger extract against
pancreatic cancer cells mainly through reactive oxygen
Species-mediated Autotic cell death. PLoS One. 10:e01266052015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Seicean A, Petrusel L and Seicean R: New
targeted therapies in pancreatic cancer. World J Gastroenterol.
21:6127–6145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nordh S, Ansari D and Andersson R: hENT1
expression is predictive of gemcitabine outcome in pancreatic
cancer: A systematic review. World J Gastroenterol. 20:8482–8490.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Poplin E, Wasan H, Rolfe L, Raponi M,
Ikdahl T, Bondarenko I, Davidenko I, Bondar V, Garin A, Boeck S, et
al: Randomized, multicenter, phase II study of CO-101 versus
gemcitabine in patients with metastatic pancreatic ductal
adenocarcinoma: Including a prospective evaluation of the role of
hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol.
31:4453–4461. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wattanawongdon W, Hahnvajanawong C, Namwat
N, Kanchanawat S, Boonmars T, Jearanaikoon P, Leelayuwat C,
Techasen A and Seubwai W: Establishment and characterization of
gemcitabine-resistant human cholangiocarcinoma cell lines with
multidrug resistance and enhanced invasiveness. Int J Oncol.
47:398–410. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jordheim LP and Dumontet C: Do hENT1 and
RRM1 predict the clinical benefit of gemcitabine in pancreatic
cancer? Biomark Med. 7:663–671. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoneyama H, Takizawa-Hashimoto A, Takeuchi
O, Watanabe Y, Atsuda K, Asanuma F, Yamada Y and Suzuki Y: Acquired
resistance to gemcitabine and cross-resistance in human pancreatic
cancer clones. Anticancer Drugs. 26:90–100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nakagawa N, Murakami Y, Uemura K, Sudo T,
Hashimoto Y, Kondo N and Sueda T: Combined analysis of intratumoral
human equilibrative nucleoside transporter 1 (hENT1) and
ribonucleotide reductase regulatory subunit M1 (RRM1) expression is
a powerful predictor of survival in patients with pancreatic
carcinoma treated with adjuvant gemcitabine-based chemotherapy
after operative resection. Surgery. 153:565–575. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bhutia YD, Hung SW, Krentz M, Patel D,
Lovin D, Manoharan R, Thomson JM and Govindarajan R: Differential
processing of let-7a precursors influences RRM2 expression and
chemosensitivity in pancreatic cancer: Role of LIN-28 and SET
oncoprotein. PLoS One. 8:e534362013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fisher SB, Fisher KE, Patel SH, Lim MG,
Kooby DA, El-Rayes BF, Staley CA III, Adsay NV, Farris AB III and
Maithel SK: Excision repair cross-complementing gene-1,
ribonucleotide reductase subunit M1, ribonucleotide reductase
subunit M2, and human equilibrative nucleoside transporter-1
expression and prognostic value in biliary tract malignancy.
Cancer. 119:454–462. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Namba T, Kodama R, Moritomo S, Hoshino T
and Mizushima T: Zidovudine, an anti-viral drug, resensitizes
gemcitabine-resistant pancreatic cancer cells to gemcitabine by
inhibition of the Akt-GSK3β-Snail pathway. Cell Death Dis.
6:e17952015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yi XP, Han T, Li YX, Long XY and Li WZ:
Simultaneous silencing of XIAP and survivin causes partial
mesenchymal-epithelial transition of human pancreatic cancer cells
via the PTEN/PI3K/Akt pathway. Mol Med Rep. 12:601–608. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng ZX, Wang DW, Liu T, Liu WX, Xia WB,
Xu J, Zhang YH, Qu YK, Guo LQ, Ding L, et al: Effects of the HIF-1α
and NF-κB loop on epithelial-mesenchymal transition and
chemoresistance induced by hypoxia in pancreatic cancer cells.
Oncol Rep. 31:1891–1898. 2014.PubMed/NCBI
|
|
16
|
Rao AR, Sindhuja HN, Dharmesh SM, Sankar
KU, Sarada R and Ravishankar GA: Effective inhibition of skin
cancer, tyrosinase, and antioxidative properties by astaxanthin and
astaxanthin esters from the green alga Haematococcus
pluvialis. J Agric Food Chem. 61:3842–3851. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakao R, Nelson OL, Park JS, Mathison BD,
Thompson PA and Chew BP: Effect of dietary astaxanthin at different
stages of mammary tumor initiation in BALB/c mice. Anticancer Res.
30:2171–2175. 2010.PubMed/NCBI
|
|
18
|
Vena F, Li Causi E, Rodriguez-Justo M,
Goodstal S, Hagemann T, Hartley JA and Hochhauser D: The MEK1/2
inhibitor pimasertib enhances gemcitabine efficacy in pancreatic
cancer models by altering ribonucleotide reductase subunit-1
(RRM1). Clin Cancer Res. 21:5563–5577. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lai IL, Chou CC, Lai PT, Fang CS, Shirley
LA, Yan R, Mo X, Bloomston M, Kulp SK, Bekaii-Saab T and Chen CS:
Targeting the Warburg effect with a novel glucose transporter
inhibitor to overcome gemcitabine resistance in pancreatic cancer
cells. Carcinogenesis. 35:2203–2213. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
D'Angelo RC, Liu XW, Najy AJ, Jung YS, Won
J, Chai KX, Fridman R and Kim HR: TIMP-1 via TWIST1 induces EMT
phenotypes in human breast epithelial cells. Mol Cancer Res.
12:1324–1233. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Díaz-López A, Díaz-Martín J, Moreno-Bueno
G, Cuevas EP, Santos V, Olmeda D, Portillo F, Palacios J and Cano
A: Zeb1 and Snail1 engage miR-200f transcriptional and epigenetic
regulation during EMT. Int J Cancer. 136:E62–E73. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cho KH, Choi MJ, Jeong KJ, Kim JJ, Hwang
MH, Shin SC, Park CG and Lee HY: A ROS/STAT3/HIF-1α signaling
cascade mediates EGF-induced TWIST1 expression and prostate cancer
cell invasion. Prostate. 74:528–536. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang W, Shi X, Peng Y, Wu M, Zhang P, Xie
R, Wu Y, Yan Q, Liu S and Wang J: HIF-1α promotes
epithelial-mesenchymal transition and metastasis through direct
regulation of ZEB1 in colorectal cancer. PLoS One. 10:e01296032015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiong H, Hong J, Du W, Lin YW, Ren LL,
Wang YC, Su WY, Wang JL, Cui Y, Wang ZH and Fang JY: Roles of STAT3
and ZEB1 proteins in E-cadherin down-regulation and human
colorectal cancer epithelial-mesenchymal transition. J Biol Chem.
287:5819–5832. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Montero TD, Racordon D, Bravo L, Owen GI,
Bronfman ML and Leisewitz AV: PPARα and PPARγ regulate the
nucleoside transporter hENT1. Biochem Biophys Res Commun.
419:405–411. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lei W, Feng XH, Deng WB, Ni H, Zhang ZR,
Jia B, Yang XL, Wang TS, Liu JL, Su RW, et al: Progesterone and DNA
damage encourage uterine cell proliferation and decidualization
through up-regulating ribonucleotide reductase 2 expression during
early pregnancy in mice. J Biol Chem. 287:15174–15192. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kaira K and Yamamoto N: Prognostic and
predictive factors in resected non-small-cell lung cancer. Expert
Opin Med Diagn. 4:373–381. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tassone P, Di Martino MT, Ventura M,
Pietragalla A, Cucinotto I, Calimeri T, Bulotta A, Neri P, Caraglia
M and Tagliaferri P: Loss of BRCA1 function increases the antitumor
activity of cisplatin against human breast cancer xenografts in
vivo. Cancer Biol Ther. 8:648–653. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
El-Khoueiry AB, Ramanathan RK, Yang DY,
Zhang W, Shibata S, Wright JJ, Gandara D and Lenz HJ: A randomized
phase II of gemcitabine and sorafenib versus sorafenib alone in
patients with metastatic pancreatic cancer. Invest New Drugs.
30:1175–1183. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kao YT, Hsu WC, Hu HT, Hsu SH, Lin CS,
Chiu CC, Lu CY, Hour TC, Pu YS and Huang AM: Involvement of p38
mitogen-activated protein kinase in acquired gemcitabine-resistant
human urothelial carcinoma sublines. Kaohsiung J Med Sci.
30:323–330. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yan Q, Chen P, Wang S, Liu N, Zhao P and
Gu A: Association between HIF-1α C1772T/G1790A polymorphisms and
cancer susceptibility: An updated systematic review and
meta-analysis based on 40 case-control studies. BMC Cancer.
14:9502014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang C and Xie K: Crosstalk of Sp1 and
Stat3 signaling in pancreatic cancer pathogenesis. Cytokine Growth
Factor Rev. 23:25–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
